ophthalmic biosimilars - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Representative image of a legal and workplace rights dispute in India after the National Human Rights Commission notices and the Supreme Court filing intensified focus on the Nashik workplace harassment and coercion case involving Tata Consultancy Services.

TCS Nashik case: NHRC directs three-year POSH audit across all TCS branches

Nexstar Media Group (NASDAQ: NXST) faces post-closing merger shock as judge halts TEGNA integration

Bally’s Corporation (NYSE: BALY) eyes evoke plc (LSE: EVOK): why a William Hill deal would reshape UK gambling

Why Lockheed Martin’s $101.6 m Army award matters more than its size suggests for LMT stock

Representative image illustrating Canada’s emergence as the preferred first-launch market for ophthalmic biosimilars like aflibercept in 2025

Read More

Pharma Industry News

How Canada became the preferred launchpad for ophthalmic biosimilars in 2025

With Yesafili’s approval, Canada is emerging as the global launchpad for ophthalmic biosimilars. Explore what’s driving this strategic shift.

byPallavi Madhiraju

July 3, 2025

web analytics